Astellas Pharma is issuing 340B covered entities refunds for overcharges on three NDCs for its prostate cancer treatment Xtandi and on four NDCs for its overactive bladder medication Myrbetriq for the period from Q3 2020 through Q2 2021.
Astellas posted the notice on the U.S. Health Resources and Services Administration (HRSA) website this week. It said it recalculated its 340B ceiling prices on the products “due to revisions made to reported Medicaid pricing data.”
Astellas, like Lilly earlier this week, said it “is not seeking reimbursement or repayment where covered entities paid a lower price than the recalculated 340B ceiling prices for the specified quarters.”
